Clay Siegall: A leader in cancer research

Cancer is among the top leading causes of death around the world. In fact, according the National Cancer Institute ” in 2016, an estimated 1,685,210 new cases of cancer will be diagnosed and 595,690 people will die from the disease.” They also state in a 2014 study that, ” an estimated 15,780 children and adolescents aged 0-19 were diagnosed with cancer and 1,960 died of this disease.” While these statistics seem scary, there’s researchers developing new treatments and searching for a cure. Continue reading to learn about a company that takes leadership in this field.

Clay Siegall, co-founder, CEO and president of Seattle Genetics, is actively seeking a cure for cancer. Under his leadership, Seattle Genetics has developed an Antibody Drug Conjugate (ADC’s). These ADC’s selectively kill off cancer cells while leaving healthy cells alive. In addition to ADC’s, they’re expanding the use of Adcetrics to diseases beyond cancer.

Siegall’s passion for helping others and in vigorous research practices, puts Seattle Genetics in the leadership position for the cancer research community. Clay Siegall, has taken this leadership, going in with the mindset of finding an end to this illness.

Starting his career as a scientist, Mr. Siegall worked for Bristol-Myer Squibb (a pharmaceutical company) and the National Cancer Institute. Mr. Siegall serves on the Board of Directors for several pharmaceutical companies such as, Alder Pharmaceuticals, Mirna Therapies, Ultragenyx, and Seattle Genetics.

After founding Seattle Genetics in 1998, Mr. Siegall lead the company into the leadership role for cancer research. He was driven by his desire to end this illness that claims the lives of hundreds of thousands every year.